Friday, 31 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > Vertex non-opioid pain drug Journavx appoved by FDA
Health and Wellness

Vertex non-opioid pain drug Journavx appoved by FDA

Last updated: January 31, 2025 1:15 am
Share
SHARE

Vertex Pharmaceuticals has recently received approval from the Food and Drug Administration for their new non-opioid pain drug, Journavx. This approval marks a significant milestone for the company and paves the way for the launch of a product that has garnered both high hopes and mixed opinions among physicians and market analysts.

Journavx is designed for the twice-daily treatment of moderate to severe acute pain, such as the kind of sharp, short-lived aches that may follow a bike accident or a surgical procedure. The FDA’s decision to approve the drug was based on the results of two late-stage trials, which showed that patients undergoing procedures like tummy tucks or bunion surgery experienced significantly less pain after taking Journavx compared to those who received a placebo. Additionally, the trials demonstrated that the drug was generally safe, with fewer adverse events reported in the Journavx group compared to the placebo group.

Priced at $31 per day, Journavx is expected to generate $1.5 billion in annual revenue by 2030, according to market analysts. This estimate does not include potential sales for chronic pain, where there is a larger market opportunity that Vertex is also exploring through ongoing clinical trials.

The approval of Journavx represents a significant advancement in the field of pain management, offering patients a non-opioid alternative for managing acute pain. With its promising efficacy and safety profile, Journavx has the potential to address unmet needs in pain management and improve the quality of life for patients experiencing acute pain.

As Vertex Pharmaceuticals prepares to launch Journavx in the market, the company is poised to make a significant impact in the healthcare industry and provide patients with a much-needed alternative to traditional pain medications. With its innovative approach to pain management, Journavx has the potential to revolutionize the way acute pain is treated and pave the way for future advancements in the field.

See also  A new drug, Voranigo, delays brain tumor progression
TAGGED:appovedDrugFDAJournavxnonopioidpainVertex
Share This Article
Twitter Email Copy Link Print
Previous Article De’Aaron Fox laughs off Kings fan’s call out for getting Tyrese Haliburton traded and Mike Brown fired before imminent trade 
Next Article Lions’ Amik Robertson Says Jets In ‘Good Hands’ W/ Aaron Glenn, Predicts ‘Great Things’
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Chappell Roan Films Music Video in NYC With Dramatic Rapunzel-Style Hairdo

Chappell Roan I'm No Damsel, Just Hair For The Drama!!! Published July 8, 2025 8:53…

July 8, 2025

Nvidia stock eyes record high, looks to unseat Apple as world’s most valuable company

Nvidia (NVDA) is making waves in the stock market, with its shares soaring to record…

October 14, 2024

The AI edge in cybersecurity: Predictive tools aim to slash response times

Cybersecurity in the modern world is more crucial than ever before. With the increasing number…

October 20, 2024

Super Micro Probed by US Following Hindenburg Report, WSJ Says

Super Micro Computer Inc. Under Investigation by US Justice Department Super Micro Computer Inc. is…

September 26, 2024

In Atlantic City, the New Jersey governor’s race was in full swing

Atlantic City, New Jersey is not only known for its vibrant nightlife and bustling boardwalk,…

November 22, 2024

You Might Also Like

Teen victim tied to Washington Square Park drug bust ID’d as recent grad who moved to NYC to start new life, internship
Crime

Teen victim tied to Washington Square Park drug bust ID’d as recent grad who moved to NYC to start new life, internship

October 31, 2025
As Medicaid work requirements loom, study finds links between coverage, better health and higher employment
Health and Wellness

As Medicaid work requirements loom, study finds links between coverage, better health and higher employment

October 31, 2025
Digital Twins Coming To Robotic Surgery
Health and Wellness

Digital Twins Coming To Robotic Surgery

October 31, 2025
Medicare, midterm elections, Vinay Prasad: Morning Rounds
Health and Wellness

Medicare, midterm elections, Vinay Prasad: Morning Rounds

October 31, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?